Medical artificial intelligence (AI) company Lunit (CEO Seo Beom-seok) announced on the 25th that it has signed a strategic partnership with global clinical trial contract research organization (CRO) CellCarta to utilize the AI biomarker platform 'Lunit Scope' in global clinical trials.
Headquartered in Montreal, Canada, Cellcarta is a leading global CRO providing precision medicine research and clinical trial support, with research facilities across the globe, including in the United States, Belgium, and China. Cellcarta boasts industry-leading expertise in integrating digital pathology and AI technologies into clinical trials. Based on its experience participating in over 1,000 clinical trials and developing over 250 immunohistochemical (IHC) assays, Cellcarta provides over 100,000 IHC assays annually.
This partnership focuses on combining Lunit's AI technology with Cellcarta's CRO expertise and global infrastructure to enable pharmaceutical companies to more easily and quickly utilize AI-based biomarker analysis in the new drug development process.
Seo Beom-seok, CEO of Lunit, said, “Through this strategic collaboration with Cellcarta, we have laid the foundation for Lunit Scope to be utilized more broadly in global clinical trials. Through collaboration with global CRO companies, we will increase the efficiency of pharmaceutical companies’ clinical trials and ultimately contribute to providing more precise and effective treatments to patients.”
“Pharmaceutical and biotech companies around the world are looking for proven AI-based pathology solutions for biomarker development and patient screening,” said Yannick Baumans, Head of Digital Pathology Solutions at Cellcarta. “This partnership will bring Lunit’s proven AI technology to our customers, providing them with a new standard in clinical trial operations.”
- See more related articles
You must be logged in to post a comment.